Filing Flows › Northwest Biotherapeutics (NWBO) › Q4 2024
Northwest Biotherapeutics (NWBO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
Northwest Biotherapeutics (NWBO) reported revenue of $231K for the fourth quarter 2024 (Q4 2024), -48% from a year earlier and -35% from the quarter before.
Northwest Biotherapeutics, Q4 2024: revenue $231K (-48% year over year), net loss $28.2M, operating cash flow −$20.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $231K | -35% | -48% |
| Operating profit | −$18.5M | — | — |
| Net earnings | −$28.2M | — | — |
| Operating cash flow | −$20.2M | — | — |
What changed
Revenue was $231K in Q4 2024, down 48% year over year and down 35% from the previous quarter.
Operating costs exceeded revenue by $18.5M, an operating margin of -8008.2%. Total costs grew 20% against a revenue fall of 48%. The fastest-growing cost line was Research & development (+41%). The quarter ended with a net loss of $28.2M, wider than the previous quarter's $19.4M loss.
Operating cash flow was −$20.2M. Non-cash charges added back $437K of depreciation and amortization and $476K of share-based compensation. Working capital and other items added $7.1M. Capital expenditures of $78K exceeded it, leaving free cash flow of −$20.3M.
Questions
What was Northwest Biotherapeutics' revenue in the fourth quarter 2024?
Northwest Biotherapeutics (NWBO) reported revenue of $231K for the fourth quarter 2024 (Q4 2024), -48% from a year earlier and -35% from the quarter before.